This study looks at how safe and effective a new medicine, TCD601, is when combined with another medicine called Belatacept. This is for people who just had a kidney transplant (called "de novo" renal transplant). TCD601 is a special medicine known as an anti-CD2 monoclonal antibody, which means it targets specific cells in your body. The study compares this new combination with the usual medicines given after a kidney transplant to see which works better.
Key Points:
- Duration: Study length and number of visits will be determined by the research staff.
- Participation: Participants must be between 18-70 years old and have a new kidney from specific types of donors.
- Risks and Benefits: Discuss with the research team to understand the potential risks and benefits of participating.
To join, you need to understand the study and sign a consent form. You must be 18-70 years old and have received a kidney from certain types of donors. If you have had a kidney transplant before, or received a kidney from a specific donor type, you cannot join this study.
How understandable was the trial content above?
Hard to understand
Easy to understand